Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.
Clinical Trials Arena2h
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...
Hype of weight loss medications: Benefits, risks and what’s often overlooked
Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.
Prescott eNews20h
Trump administration nixes plan to cover anti-obesity drugs through Medicare – Associated Press
Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home in Front Royal, Va., on Friday, March 1, ...